Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
ADMA Biologics Inc has a consensus price target of $15.5 based on the ratings of 4 analysts. The high is $20 issued by Cantor Fitzgerald on September 20, 2024. The low is $10 issued by Raymond James on May 10, 2024. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, HC Wainwright & Co., and Cantor Fitzgerald on September 20, 2024, August 12, 2024, and August 9, 2024, respectively. With an average price target of $19.33 between Cantor Fitzgerald, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied -3.53% downside for ADMA Biologics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for ADMA Biologics (NASDAQ:ADMA) was reported by Cantor Fitzgerald on September 20, 2024. The analyst firm set a price target for $20.00 expecting ADMA to fall to within 12 months (a possible -0.20% downside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for ADMA Biologics (NASDAQ:ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics reiterated their overweight rating.
The last upgrade for ADMA Biologics Inc happened on November 11, 2021 when Raymond James raised their price target to $5. Raymond James previously had an outperform for ADMA Biologics Inc.
There is no last downgrade for ADMA Biologics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.
While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a reiterated with a price target of $20.00 to $20.00. The current price ADMA Biologics (ADMA) is trading at is $20.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.